The NM_000152.5:c.457_465del variant in GAA is predicted to cause a change in the length of the protein (p.Arg154_Thr156del) due to an in-frame deletion of 3 amino acids in a non-repeat region (PM4). One patient with this variant and a diagnosis of Pompe disease has been reported with decreased enzyme activity and treated by enzyme replacement therapy (PMID: 18757064, 23013746) (PP4). This individual is compound heterozygous for the variant and a pathogenic variant in GAA, c.-32-13T>G, phase unknown (PMID: 18757064, 23013746) PM3_Supporting. Computational evidence is conflicting; the PROVEAN score is -11.8 (meeting the threshold of <-2.5 for deleterious), and Mutation Taster predicts that this variant is a ”polymorphism”. Therefore, neither PP3 nor BP4 is met. When expressed in cultured cells, this variant results in 0.5% wild type GAA activity and is abnormally synthesized and processed (PMID 22644586) (PS3_Moderate). In summary, this variant meets the criteria to be classified as likely pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases VCEP (Specifications Version 2.0): PM4, PS3_Moderate, PM2_Supporting, PM3_Supporting. (Classification approved by the ClinGen Lysosomal Diseases VCEP on June 17, 2024)